Kymer­a's top drug hunter leaves for Alex­is Borisy's Curie.Bio; What’s done is Dunn: FDA neu­ro­science leader bows out

By day two of his job as CSO part­ner at Alex­is Borisy’s new in­vest­ment and biotech ser­vices firm, Chris De Savi had al­ready gone through the due dili­gence with mul­ti­ple founders look­ing to get their ideas off the ground and in­to the ex­per­i­men­ta­tion phase.

The for­mer Kymera Ther­a­peu­tics drug dis­cov­ery leader joined Curie.Bio this week to prop up new biotech founders and pro­vide ex­per­tise to get their sci­ence and tech up to snuff. He’s the first of what will like­ly be about half a dozen CSO part­ners to be hired at Curie this year as the com­pa­ny looks to build out a 50- to 60-per­son team that helps ear­ly-stage en­tre­pre­neurs turn their ideas in­to 12- to 24-month ex­per­i­men­tal plans that can get them to da­ta that will woo Se­ries A in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER